Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.56 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 13/20 | 0.55 |
| ▸ | CNR1 | P21554 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025603 | 0.88 | TAS2R14 (0.58) | TAS2R14CNR2MEN1KMT2A | |
| SCHEMBL4920994 | 0.83 | CNR2 (0.63) | TAS2R14CNR2CNR1MEN1KMT2A | |
| SCHEMBL8281042 | 0.82 | MEN1 (0.51) | CNR2MEN1KMT2A | |
| SCHEMBL4786730 | 0.80 | CXCR3 (0.58) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL8281044 | 0.78 | MEN1 (0.51) | CNR2MEN1KMT2A | |
| SCHEMBL28729777 | 0.78 | TAS2R14 (0.80) | TAS2R14CXCR3PTGESTAS2R8CNR2 | |
| SCHEMBL4917430 | 0.77 | CNR2 (0.68) | TAS2R14CNR2CNR1MEN1KMT2A | |
| SCHEMBL6497006 | 0.77 | MAPK1 (0.65) | MEN1KMT2A | |
| SCHEMBL984791 | 0.77 | TAS2R14 (0.71) | TAS2R14CXCR3CNR2MEN1KMT2A | |
| SCHEMBL9504529 | 0.76 | MEN1 (0.48) | CNR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | TAS2R14 4808/4885CXCR3 248/4885PTGES 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.